专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明公开

EP2288616A1 PEPTIDYLARGININE DEIMINASE (PAD) INHIBITORS 有权
标题翻译：哌啶二脱氨酶（PAD）抑制剂
公开(公告)号：EP2288616A1
公开(公告)日：2011-03-02
申请号：EP09788195.7
申请日：2009-06-15
申请人： Chiralix B.V. , ModiQuest B.V. , Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum
发明人： BLAAUW, Richard Hendrik , PRUIJN, Gerardus Jozef Maria , RAATS, Jozef Maria Hendrik , RUTJES, Floris Petrus Johannes Theodorus , DRIJFHOUT, Jan Wouter
IPC分类号： C07K7/06 , C07K7/08 , C07K14/47 , A61K38/08 , A61K38/10 , A61K38/17
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K14/47 , C07K14/4713
摘要： The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.
摘要翻译：本发明涉及适合用作抗自身免疫疾病如RA的药物的PAD抑制剂。

32. 发明公开

EP2089513A1 USE OF A VARICELLOVIRUS TAP-INHIBITOR FOR THE INDUCTION OF TUMOR- OR VIRUS-SPECIFIC IMMUNITY AGAINST TEIPP 审中-公开
标题翻译： USING A水痘TAP抑制剂诱导病毒或肿瘤特异性免疫AGAINST TEIPP作者
公开(公告)号：EP2089513A1
公开(公告)日：2009-08-19
申请号：EP07851888.3
申请日：2007-12-07
申请人： Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum
发明人： WIERTZ, Emmanuel Jacques Henri Joseph , KOPPERS-LALIC, Danijela , GOULMY, Elsa Afra Julia Maria , OFFRINGA, Rienk , VAN HALL, Thorbald van Hall Thorbald
IPC分类号： C12N5/08 , C07K14/03 , A61K39/245
CPC分类号： C12N5/0639 , A61K39/12 , A61K39/25 , C07K14/005 , C12N7/00 , C12N2710/16322 , C12N2710/16622 , C12N2710/16722 , C12N2710/16734
摘要： The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity.

33. 发明公开

EP1500709A1 Means and methods for detecting a risk of infarction related to atherosclerosis 审中-公开
标题翻译：方法和装置，用于确定梗死的风险，这是连接到动脉硬化
公开(公告)号：EP1500709A1
公开(公告)日：2005-01-26
申请号：EP03077299.0
申请日：2003-07-21
申请人： Academisch Ziekenhuis bij de Universiteit van Amsterdam , Leids Universitair Medisch Centrum
发明人： Reitsma, Pieter Hendrik , Rosendaal, Frits Richard
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The invention provides a method for determining whether a subject is at risk of undergoing an infarction related to atherosclerosis comprising measuring an inflammation parameter in a sample obtained from said subject and determining whether the value of said inflammation parameter is indicative for said risk. Said sample preferably comprises a whole blood sample. More preferably, said inflammation parameter comprises an inflammation parameter of a cell and/or derivative thereof present in said sample, such as the amount of protein and/or RNA present upon and/or within such cells/derivatives. Additionally, an excreted product produced by said cell/derivative may be measured. The invention furthermore provides a method for quantifying at least one target nucleic acid in a sample, comprising incubating said sample with at least one probe capable of annealing to said target nucleic acid, amplifying annealed probes and quantifying said probes, characterized in that said sample comprises a whole blood sample.
摘要翻译：本发明提供了用于确定性采矿的方法无论是受试者处于在与动脉粥样硬化来自所述受试者和确定性采矿无论的所述炎症参数的值是表示对所述风险获得的样品中，其包括炎症参数测量梗死经历的风险。所述样品优选包括全血样品。更优选地，所述炎症参数的小区和/或它们的衍生物存在于所述样品中，：炎症参数，如蛋白质的量和/或存在于和/或搜索细胞/衍生物内RNA包含。另外，在由所述细胞产生的排泄物的产品/衍生物可被测量。本发明进一步更提供用于定量样品中的至少一种靶核酸，包括孵育所述样品与能够退火到所述至少一个探针靶核酸，扩增退火探针和定量所述探针的方法，在所述样品包含其特点全血样本。

34. 发明公开

EP1222933A1 Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway 审中-公开
标题翻译：教育和/或通过调节Wnt信号通路减少在肺erkranketen新的肺组织的
公开(公告)号：EP1222933A1
公开(公告)日：2002-07-17
申请号：EP01200123.6
申请日：2001-01-15
申请人： Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum
发明人： The designation of the inventor has not yet been filed
IPC分类号： A61K48/00 , A61K38/02 , C07K14/705 , C07K16/18 , C12N5/00
CPC分类号： C07K14/705 , A61K48/00 , A61K2039/505
摘要： The present invention provides a means to influence the formation and/or reduction of new lung cells, by influencing a Wnt-pathway in an alveolar type II cell and/or alveolar type II tumor cell from said lung. Therefore, the invention provides a composition comprising a nucleic acid capable of binding at least a functional part of a nucleic acid encoding a protein which is involved in a Wnt-pathway in said cell, said binding influencing said Wnt-pathway.
A composition of the invention may also comprise a protein capable of binding at least a functional part of a protein which is involved in a Wnt-pathway in said cell, or at least a functional part of a nucleic acid encoding a protein which is involved in a Wnt-pathway in said cell, said binding influencing said Wnt-pathway.
A composition of the invention is suitable for the preparation of a medicament against emphysema, Respiratory Distress Syndrome and/or lung cancer.
摘要翻译：本发明提供了一种手段来影响新肺细胞的形成和/或还原，通过对从肺说肺泡II型细胞和/或肺泡II型细胞瘤在影响一个Wnt途径。因此，本发明提供一种组合物包含核酸能够至少一个核酸编码蛋白质的所有其在细胞中的所述A Wnt途径参与其中，所述结合影响所述Wnt途径的功能性部分结合。因此，本发明的组合物可包含能够至少一个蛋白的功能部分中的所有其以所述细胞中Wnt途径参与其中，或编码蛋白质的所有其在涉及到核酸中的至少一个功能性部分结合的蛋白质在细胞中的Wnt途径说，所述结合影响所述Wnt途径。本发明的组合物适用于对肺气肿，呼吸窘迫综合征和/或肺癌的药物中的用途。

35. 发明公开

EP1218028A1 DENDRITIC CELLS ACTIVATED IN THE PRESENCE OF GLUCOCORTICOID HORMONES ARE CAPABLE OF SUPPRESSING ANTIGENSPECIFIC T CELL RESPONSES 有权
标题翻译：激活糖皮质激素激素的存在树突状细胞能够抗原特异性T细胞应答来抑制
公开(公告)号：EP1218028A1
公开(公告)日：2002-07-03
申请号：EP00971883.4
申请日：2000-10-04
申请人： Leids Universitair Medisch Centrum
发明人： REA, Delphine, Gabrielle, Josette , MELIEF, Cornelis, Johannes, Maria , OFFRINGA, Rienk
IPC分类号： A61K39/00 , A61K35/14 , C12N5/08
CPC分类号： C12N5/064 , A61K2035/122 , A61K2039/5154 , A61K2039/5158 , C12N2501/052 , C12N2501/22 , C12N2501/23 , C12N2501/39 , C12N2501/505 , C12N2501/52
摘要： The present invention provides novel methods for immunotherapy. The invention provides immune cells and methods to generate them, with the capacity to at least in part reduce an immune response in a host. In one aspect, the invention provides a method for generating a dendritic cell with the capacity to tolerize a T-cell for antigen the T-cell was specific for including culturing peripheral blood monocytes from an individual to differentiate into dendritic cells, activating the dendritic cells in the presence of a glucocorticoid hormone and loading the activated dendritic cell with the antigen the T-cell was specific for.

36. 发明授权

EP3215522B1 T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF 有权转让
公开(公告)号：EP3215522B1
公开(公告)日：2021-12-01
申请号：EP15816508.4
申请日：2015-11-02
发明人： HEEMSKERK, Mirjam, H.M. , FALKENBURG, J.H., Frederik
IPC分类号： C07K14/725 , C07K7/08 , A61K48/00 , A61K39/00

37. 发明公开

EP3030665A1 RECOMBINANT AAV-CRUMBS HOMOLOGUE COMPOSITION AND METHODS FOR TREATING LCA-8 AND PROGRESSIVE RP 有权
标题翻译：重组AAV-CRUMBS同源组合物和治疗LCA-8和进展性RP的方法
公开(公告)号：EP3030665A1
公开(公告)日：2016-06-15
申请号：EP14761426.7
申请日：2014-08-05
申请人： Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum
发明人： WIJNHOLDS, Jan , PELLISSIER, Lucie Pierrette Françoise
IPC分类号： C12N15/86 , A61K48/00 , C07K14/47
CPC分类号： C07K14/705 , A01K67/0276 , A01K2217/075 , A01K2217/203 , A01K2227/105 , A01K2267/03 , A61K35/76 , A61K48/005 , C07K14/47 , C12N15/86 , C12N2750/14132 , C12N2750/14143 , C12N2750/14171 , C12N2830/48
摘要： The present invention relates to a Crumbs homologue (CRB) therapeutic for use as a medicament or in a method of treatment or prophylaxis, for example in the treatment or prophylaxis of a retinal disorder due to mutations in the Crumbs homologue-1 (CRB1) gene, such as Leber's congenital amaurosis 8 (LCA8) or retinitis pigmentosa 12 (RP12). In particular, the present invention relates to a recombinant viral vector comprising CRB2 or modified non-toxic forms of either CRB1 or CRB3 that resemble CRB2.
摘要翻译：本发明涉及用作药物或在治疗或预防方法中使用的面包屑同系物（CRB）治疗剂，例如治疗或预防由于Crumbs同系物-1（CRB1）基因突变引起的视网膜病症，例如莱伯氏先天性黑蒙8（LCA8）或色素性视网膜炎12（RP12）。特别地，本发明涉及包含CRB2或类似CRB2的CRB1或CRB3的修饰的无毒形式的重组病毒载体。

38. 发明公开

EP2812691A1 CELL DEATH ASSAY 有权
标题翻译：细胞死亡测定
公开(公告)号：EP2812691A1
公开(公告)日：2014-12-17
申请号：EP13710587.0
申请日：2013-02-06
申请人： HQ Medical (Netherlands) B.V. , Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum
发明人： MARING, Markwin Hendrik , LÖWIK, Clemens Waltherus Gerardus , VAN BEEK, Ermond Reijer
IPC分类号： G01N33/50
摘要： The present invention relates to a method for detecting cell death using a luminescent compound; to the luminescent compounds for particular uses; to a kit comprising compounds and to a protein. The method is applicable for detecting cell death, essentially regardless of the mechanism through which cell death occurred or is occurring and is therefore not limited e.g. to detecting cell death resulting from only one mechanism selected from apoptosis and necrosis.
摘要翻译：本发明涉及使用发光化合物检测细胞死亡的方法; 涉及用于特定用途的发光化合物; 涉及包含所述化合物和蛋白质的试剂盒。该方法适用于检测细胞死亡，基本上不管细胞死亡发生或正在发生的机制如何，因此不限于例如细胞死亡。检测仅由选自凋亡和坏死的一种机制引起的细胞死亡。

39. 发明公开

EP2275817A1 PROTEOLYTIC ENZYMES IN DIAGNOSIS OF KIDNEY DISORDERS 审中-公开
标题翻译：维他命C酶
公开(公告)号：EP2275817A1
公开(公告)日：2011-01-19
申请号：EP10180116.5
申请日：2001-05-17
申请人： Nederlandse Organisatie voor Toegepast -Natuurwetenschappelijk Onderzoek TNO , Leids Universitair Medisch Centrum
发明人： Verheijen, Johan Hendrikus , Hanemaaijer, Jan Roeland Occo , Diamant, Michaela
IPC分类号： G01N33/573 , C12Q1/37
CPC分类号： C12Q1/37 , G01N33/573 , G01N2333/96486 , Y10S436/811 , Y10S530/834
摘要： The present invention relates to a method for determining whether a urine sample has been obtained from a subject suffering from a kidney disorder involving kidney damage. The method is based on determining the level of a proteolytic enzyme in urine from the subject.sample and optionally comparing this level with a reference value. The proteolytic enzyme preferably is a matrix metalloproteases, in particular MMP-2 or MMP-9. The method is particularly suitable for subjects with a condition or disorder that is associated with an increased risk of kidney disorders, such as diabetes. The method may adavnatagcously be applied for early detection of kidney damage, in particular when the subject does not yet show any sign of microalbuminuria. The method may also be applied to a subject undergoing dialysis for determining whether the subject is suffering from remodelling of the peritoneal membrane. Thus, the method is particularly suited for patients undergoing continuous ambulatory peritoneal dialysis.
摘要翻译：本发明涉及一种用于确定是否从患有肾损害的肾脏疾病的受试者获得尿样的方法。该方法基于确定来自受试者样品的尿液中的蛋白水解酶的水平，并且可选地将该水平与参考值进行比较。蛋白水解酶优选是基质金属蛋白酶，特别是MMP-2或MMP-9。该方法特别适用于与肾脏疾病风险增加（如糖尿病）相关的疾病或病症的受试者。该方法可以广泛应用于早期检测肾损伤，特别是当受试者尚未显示微量白蛋白尿的任何迹象时。该方法还可以应用于经历透析的受试者以确定受试者是否患有腹膜的重塑。因此，该方法特别适用于进行连续不卧床腹膜透析的患者。

40. 发明公开

EP2201027A2 VIRAL MODIFICATION OF REOVIRIDAE 审中-公开
标题翻译：呼肠弧病毒改性
公开(公告)号：EP2201027A2
公开(公告)日：2010-06-30
申请号：EP08839407.7
申请日：2008-10-16
申请人： Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum
发明人： HOEBEN, Robert, Cornelis , VAN DEN WOLLENBERG, Diana, Johanna, Maria
IPC分类号： C07K14/14 , C12N7/02 , A61K35/76 , A61K39/15
CPC分类号： C07K14/005 , A61K35/13 , A61K2039/525 , A61K2039/5256 , C07K2319/21 , C12N7/00 , C12N2720/12222 , C12N2720/12252 , C12N2740/15043 , C12N2810/00 , C12N2810/40
摘要： The present invention provides a reverse genetics system for viruses belonging to the Reoviridae (i.e. Reoviruses), various uses thereof, genetically modified Reoviruses, Reovirus selection/production and propagation systems, medicaments and vaccines.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式